Abiranamo 250mg (Generic Zytiga) Melbourne — Abiraterone Acetate for Prostate Cancer | Victoria, Australia 2026
Product Details
Abiranamo 250mg contains Abiraterone Acetate 250mg, an androgen biosynthesis inhibitor used in combination with corticosteroids for the treatment of specific types of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), as prescribed by an oncology specialist.
At Unnati Pharmax, we export high-quality generic Abiraterone tablets manufactured in WHO-GMP-certified Indian facilities to customers in Melbourne, Victoria, Australia, and other international destinations, subject to local import regulations.
Product Specifications
| Brand Name | Abiranamo 250mg |
| Generic Name | Abiraterone Acetate |
| Strength | 250 mg |
| Dosage Form | Tablets |
| Therapeutic Category | Oncology |
| Indications | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Sensitive Prostate Cancer (mCSPC), as prescribed |
| Drug Class | Androgen Biosynthesis Inhibitor (CYP17 Inhibitor) |
| Route of Administration | Oral |
| Storage | Store below 25°C in a cool, dry place away from moisture and sunlight |
| Prescription Required | Yes |
| Manufacturer | Indian WHO-GMP Certified Manufacturer |
| Export Availability | Melbourne, Victoria, Australia & International Markets |
Key Features
- Contains Abiraterone Acetate 250mg
- Generic alternative to Zytiga®
- Used for the treatment of eligible patients with advanced prostate cancer under specialist supervision
- Oral tablet formulation
- Manufactured in WHO-GMP-certified facilities
- Quality-tested with export-grade packaging
- Competitive pricing for international markets
- Available for pharmacies, hospitals, wholesalers, and licensed importers
- Secure worldwide shipping from India
- Export documentation and parcel tracking available
Industry Update
Abiraterone acetate remains a key hormonal therapy for the treatment of advanced prostate cancer and is widely incorporated into international oncology guidelines for appropriate patients with mCRPC and mCSPC. Ongoing clinical research continues to evaluate optimal sequencing and combination strategies with androgen receptor inhibitors, chemotherapy, and targeted therapies to improve long-term outcomes. The increasing availability of high-quality generic abiraterone has expanded access to treatment globally while helping reduce healthcare costs. Treatment should always be initiated and monitored by an oncology specialist according to current clinical guidelines.
Melbourne's Peter MacCallum Cancer Centre — Australia's only dedicated cancer hospital and one of the world's top ten — alongside the Royal Melbourne Hospital, Alfred Hospital, and Monash Health manage prostate cancer for Victoria's 6.7 million population. Melbourne's diverse Greek, Italian, Chinese, Indian, and Vietnamese communities create distinct prostate cancer demographic patterns. Australia has one of the world's highest prostate cancer incidence rates from widespread PSA screening. Abiranamo 250mg provides Melbourne's advanced prostate cancer patients with life-extending Abiraterone at dramatically reduced cost versus Victorian pharmacy brand pricing.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com

FAQ 1: How does Peter MacCallum Cancer Centre's world-leading prostate cancer programme shape Abiranamo use for Melbourne patients?

FAQ 2: How does Melbourne's large Greek and Italian community — with specific prostate cancer dietary risk factors — engage with Abiranamo?

FAQ 3: What is the PBS listing for Abiranamo in Australia and how does it affect Melbourne patients?

FAQ 4: How does Melbourne's significant Chinese community engage with prostate cancer screening and Abiranamo treatment?

FAQ 5: How does Melbourne's world-class coffee culture interact with Abiranamo 250mg use?
Website
Email Id
Contact Number
+91-8265041513
Abiranamo-250-mg-Generic-Zytig-Melbourne